2011 second-quarter and 2011 first-half consolidated net sales by productAppendix 2:

2011 second-quarter and 2011 first-half consolidated net sales by geographic region and product Appendix 3:

Consolidated net sales by business segmentAppendix 4:

Net sales of Growth PlatformsAppendix 5:

2011 second-quarter and 2011 first-half business net income statement Appendix 6:

Reconciliation of business net income to net income attributable to equity holders of SanofiAppendix 7:

2011 second-quarter and 2011 first-half consolidated income statementAppendix 8:

Change in net debtAppendix 9:

Simplified consolidated balance sheetAppendix 10:

Definitions Appendix 1: 2011 second-quarter and first-half consolidated net sales by product (euro million)Q2 2011 net salesChange at constant exchange ratesChange on a reported basisLantus®

969

+14.5%

+4.6%Apidra®

53

+29.5%

+20.5%Insuman®

33

+3.0%

0.0%Amaryl𪠝

-9.5%

-13.5%
Total Diabetes1,168+12.4%+3.5%Lovenox®

536

-34.8%

-38.1%Plavix®

510

-2.4%

-5.2%Taxotere®

204

-64.5%

-65.9%Aprovel®

343

+3.6%

+1.5%Eloxatin®

248

+194.7%

+163.8%Multaq®